

Commentary

Following Russia's invasion of Ukraine, global assets sought safety, with the AUD and NZD's lower perceived geopolitical risk and rhetoric around central bank tightening leading to a strong appreciation in March (AUD +3.0%), (NZD +2.6%). Global equities rebounded (+2.2% in USD, but -1.3% in AUD) with Energy, Utilities, Healthcare and Materials outperforming, whilst Consumer Staples, Communication Services, Financials and Consumer Discretionary underperformed. US equities outperformed broader global markets (0.0%), maintaining distance from geopolitical risks and reporting strong employment data. European equities underperformed (-3.5%) due to geopolitical risks and resulting inflation.

Asian equities underperformed broader global markets (-5.3%) with Chinese equities the major underperformer (-11.4%). This stemmed from poor macro data and China's zero COVID-19 policy resulting in major regional lockdowns. Japan underperformed (-3.9%) as the Yen depreciated and the Bank of Japan indicated the potential to intervene and provide future assistance.

Elsewhere, Brent Crude (+6.9% in USD) and Gold (+1.5%) were up and the US Dollar (+1.7%) was strong.

Key contributors included:

- Oil/Natural Gas cluster, notably EQT Corp and Coterra contributed to portfolio performance in March fuelled by the recent surge in commodity prices amid Russian supply disruptions, with both companies benefitting from the renewed demand outlook for US gas exports.
- Teck Resources within the Materials cluster, continued to benefit from strong investor sentiment around the release of the company's 4Q21 results in February in addition to sell side analyst upgrades during the month as a consequence of surging demand for metallurgical (steel-making) coal and record high copper prices.
- Tail Risk cluster including Gold as well as miners Newcrest and Barrick contributed to the portfolio over the month as geopolitical tension played on investor sentiment, with gold benefitting as a perceived safe haven.

Net performance (%)

	Fund	Benchmark	Difference
1 month	-4.3	-1.3	-3.0
3 month	-7.3	-8.4	1.1
Year to date	-7.3	-8.4	1.1
1 year	-1.4	8.8	-10.3
3 year p.a.	7.7	11.7	-4.0
5 year p.a.	8.8	12.0	-3.2
Inception p.a.	9.5	10.4	-0.9

Past performance is not a reliable indicator of future performance. Returns are quoted in AUD and net of applicable fees, costs and taxes. All p.a. returns are annualised. The inception date of the Antipodes Global Fund – Long (Class P) is 1 August 2015. In order to show performance since the fund's inception, the performance for the period 1 July 2015 to 31 July 2015 is derived from Antipodes Global Fund – Long (Class I) and is adjusted to reflect the fees of Class P.

Performance & risk summary¹

Average net exposure	89.0%
Upside capture ratio	93
Downside capture ratio	81
Portfolio standard deviation	10.8%
Benchmark standard deviation	10.7%
Sharpe ratio	0.93

¹ All metrics are based on gross of fee returns in AUD terms. The upside/downside capture ratio is the percentage of benchmark performance captured by the fund during months that the benchmark is up/down. Standard deviation is a measure of risk with a smaller figure indicating lower return volatility. The Sharpe ratio measures returns on a risk adjusted basis with a figure > 1 indicating a higher return than the benchmark for the respective levels of return volatility

Performance contribution² (%)

	1 month
Long	-3.9%
Currency	-0.3%


² Based on gross returns in AUD

- Internet/Software – Developed Markets cluster including Meta Platforms and Oracle. Investor sentiment turned positive for Meta over the month, following the notable sell-off in February after weaker than expected earnings. The rebound is in line with Antipodes' thesis, Meta Platforms' core assets (Facebook, Instagram, WhatsApp and Messenger) remain dominant with a long runway of monetisation. Oracle reported 3Q22 results broadly in line with expectations, with the stock initially declining before rebounding and finishing the month higher. Oracle's relationships with TikTok and in the healthcare sector also remain a source of investor encouragement.

Key detractors included:

- Internet/Software – Asia/EM cluster, including JD.com, Tencent and KE Holdings. Upon releasing results which were in line with analyst expectations, JD.com and Tencent revealed slowing revenue growth in a challenging year for Chinese internet companies. Fears of slowing economic growth, continued regulatory impacts and prospective delisting announcements continue to weigh heavily on investor sentiment. Antipodes remains broadly constructive on China exposures with policy rhetoric shifting and commentary from senior Chinese policy makers recently turning more constructive towards supporting the economy.
- Consumer Cyclical – Developed Markets cluster including ING Groep and UniCredit with sentiment continuing to remain depressed in reaction to European banks Russian exposure. Despite the geopolitical uncertainty, we view the market reaction as disproportionate relative to exposure and against the strong capital positions of both companies.
- Hardware cluster, including Mediatek which saw investor profit taking in March after a period of strong performance. The shift in sentiment was also explained by recent negative datapoints and media reports indicating weaker Chinese domestic handset volume numbers in February. There has been no change to Antipodes' thesis, noting Mediatek's resilient growth and margin outlook are multifaceted, and include market share gains from the ongoing transitions to 5G, growth of other wireless cycles such as wifi, and other businesses lines outside of handset hardware.

Top & bottom sector contribution^{2,3} (%)



³ Antipodes classification

Fund facts


Characteristics	
Investment manager	Antipodes Partners
Inception date	1 July 2015
Benchmark	MSCI All Country World Net Index in AUD
Management fee	1.20% p.a.
Performance fee	15% of net return in excess of benchmark
Buy/Sell spread	±0.30%
Minimum investment	AUD \$25,000
Distribution	Annual, 30 June
Asset value	
Fund AUM	\$786m
Strategy AUM	\$3.291m
Unit redemption price	1.0535

Asset allocation⁴

	Equities - Long	Other - Long
Weight (%)	94.5	-
Count	62	-
Avg. weight (%)	1.5	-
Top 10 (%)	28.9	-
Top 30 (%)	68.4	-

⁴ Call (put) options represented as the current option value (delta adjusted exposure)

Sector exposure^{4,5} (%)




⁵ Antipodes classification

Top 10 equity longs⁴ (%)

Name	Country	Weight
EQT	United States	3.2
Merck	United States	3.1
Frontier Communications Parent	United States	2.9
Coterra Energy	United States	2.9
Sanofi	France	2.9
Microsoft	United States	2.8
Teck Resources	Canada	2.8
SAP	Germany	2.8
Oracle	United States	2.8
Siemens	Germany	2.7

Currency exposure^{4,6} (%)



⁶ Where possible, regions, countries and currencies classified on a look through basis

Regional exposure^{4,5,6} (%)

Region	Long
North America	46.1
Western Europe	25.5
- Eurozone	20.6
- United Kingdom	4.1
- Rest Western Europe	0.7
Developing Asia/EM	13.2
- China/Hong Kong	11.6
- India	1.6
Developed Asia	7.6
- Korea/Taiwan	4.5
- Japan	3.1
Australia	2.2
Total Equities	94.5
Cash	5.5
Totals	100.0

Market cap exposure⁴ (%)

Band	Weight
Mega (>\$100b)	35.3
Large (>\$25b <\$100b)	27.6
Medium (>\$5b <\$25b)	28.4
Small (<\$5b)	3.3

Investment Manager

- Global pragmatic value manager, long only and long-short
- Structured to reinforce alignment between investors and the investment team
- We attempt to take advantage of the market's tendency for irrational extrapolation, identify investments that offer a high margin of safety and build portfolios with a capital preservation focus

Fund Ratings



Fund features

- Objective to achieve absolute returns in excess of the benchmark over the investment cycle (typically 3-5 years)
- In the absence of finding individual securities that meet minimum risk-return criteria, cash may be held to maximum 25%
- Flexibility to hedge for risk management purposes:
 - Currency exposure of the underlying stock position (net short currency position not permitted)
 - Equity market exposure via exchange traded derivatives (limited to 10% of NAV)
 - Leverage not permitted

Further information

☎ 1300 010 311

✉ invest@antipodespartners.com

Australia Head Office

Antipodes Partners Limited
Level 35, 60 Margaret St
Sydney NSW 2000
Australia

UK Office

Antipodes Partners Limited
6th Floor, Nova North
11 Bressenden Place
London SW1E 5BY UK

Disclaimer

This communication is prepared by Antipodes Partners Limited ('Antipodes') (ABN 29 602 042 035, AFSL 481580) as the investment manager of the Antipodes Global Fund – Long (ARSN 118 075 764) ('the Fund'). Pinnacle Fund Services Limited ('PFSL') (ABN 29 082 494 362, AFSL 238371) is the product issuer of the Fund. PFSL is not licensed to provide financial product advice. PFSL is a wholly-owned subsidiary of the Pinnacle Investment Management Group Limited ('Pinnacle') (ABN 22 100 325 184). The Product Disclosure Statement ('PDS') and Target Market Determination ('TMD') of the Fund are available via below links. Any potential investor should consider the PDS and TMD before deciding whether to acquire, or continue to hold units in, the Fund.

Link to [Product Disclosure Statement](#)

Link to [Target Market Determination](#)

For historic TMD's please contact Pinnacle client service Phone 1300 010 311 or Email service@pinnacleinvestment.com

This communication is for general information only. It is not intended as a securities recommendation or statement of opinion intended to influence a person or persons in making a decision in relation to investment. It has been prepared without taking account of any person's objectives, financial situation or needs. Any persons relying on this information should obtain professional advice before doing so. Past performance is for illustrative purposes only and is not indicative of future performance. Options exposure represents the market downside. For put options (typically used to limit potential downside) delta-adjusted exposure is used and for call options (typically used to capture potential upside) exposure is calculated using the current option value. Unless otherwise specified, all amounts are in Australian Dollars (AUD).

Whilst Antipodes, PFSL and Pinnacle believe the information contained in this communication is reliable, no warranty is given as to its accuracy, reliability or completeness and persons relying on this information do so at their own risk. Subject to any liability which cannot be excluded under the relevant laws, Antipodes, PFSL and Pinnacle disclaim all liability to any person relying on the information contained in this communication in respect of any loss or damage (including consequential loss or damage), however caused, which may be suffered or arise directly or indirectly in respect of such information. This disclaimer extends to any entity that may distribute this communication.

Any opinions and forecasts reflect the judgment and assumptions of Antipodes and its representatives on the basis of information available as at the date of publication and may later change without notice. Any projections contained in this presentation are estimates only and may not be realised in the future.

Unauthorised use, copying, distribution, replication, posting, transmitting, publication, display, or reproduction in whole or in part of the information contained in this communication is prohibited without obtaining prior written permission from Antipodes. Pinnacle and its associates may have interests in financial products and may receive fees from companies referred to during this communication.

Zenith Disclaimer: The Zenith Investment Partners ('Zenith') (ABN 27 103 132 672, AFSL 226872) rating (assigned Antipodes Global Fund – Long – November 2021) referred to in this piece is limited to "General Advice" (s766B Corporations Act 2001) for Wholesale clients only. This advice has been prepared without taking into account the objectives, financial situation or needs of any individual, including target markets of financial products, where applicable, and is subject to change at any time without prior notice. It is not a specific recommendation to purchase, sell or hold the relevant product(s). Investors should seek independent financial advice before making an investment decision and should consider the appropriateness of this advice in light of their own objectives, financial situation and needs. Investors should obtain a copy of, and consider the PDS or offer document before making any decision and refer to the full Zenith Product Assessment available on the Zenith website. Past performance is not an indication of future performance. Zenith usually charges the product issuer, fund manager or related party to conduct Product Assessments. Full details regarding Zenith's methodology, ratings definitions and regulatory compliance are available on our Product Assessments and at [Fund Research Regulatory Guidelines](#).

Lonsec Disclaimer: The Lonsec Rating (assigned March 2021) Lonsec Research presented in this document is published by Lonsec Research Pty Ltd ('Lonsec') (ABN 11 151 658 561, AFSL 421445). The Rating is limited to "General Advice" (as defined in the Corporations Act 2001 (Cth)) and based solely on consideration of the investment merits of the financial products. Past performance information is for illustrative purposes only and is not indicative of future performance. They are not a recommendation to purchase, sell or hold Antipodes products, and you should seek independent financial advice before investing in these products. The Ratings are subject to change without notice and Lonsec assumes no obligation to update the relevant documents following publication. Lonsec receives a fee from the Fund Manager for researching the products using comprehensive and objective criteria. For further information regarding Lonsec's Ratings methodology, please refer to our website at <https://www.lonsec.com.au/fund-manager/investment-product-ratings>.

Morningstar Disclaimer: © 2022 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice or 'classservice' have been prepared by Morningstar Australasia Pty Ltd ('Morningstar') (ABN 95 090 665 544, AFSL 240892) and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. Refer to Morningstar Financial Services Guide (FSG) for more information at <https://cdn.morningstar.com.au/mca/s/fsg.pdf>. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement (Australian products) or Investment Statement (New Zealand products) before making any decision to invest. Morningstar publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Past performance is for illustrative purposes only and is not indicative of future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ('ASXO') (ACN 004 523 782).

Antipodes Global Fund – Long (Class P) received a Morningstar Analyst Rating™ of 'Bronze' in May 2021.